Welcome to our dedicated page for Whitehawk Therapeutics SEC filings (Ticker: WHWK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Whitehawk Therapeutics, Inc. (Nasdaq: WHWK) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Whitehawk is a clinical-stage oncology therapeutics company focused on antibody-drug conjugate (ADC) cancer treatments, and its filings offer insight into financial results, development plans and corporate activities related to this strategy.
Among the key documents available are current reports on Form 8-K, which Whitehawk has used to furnish press releases announcing quarterly financial results and recent highlights. These filings reference information such as research and development spending, progress toward Investigational New Drug (IND) submissions for ADC programs like HWK-007 and HWK-016, and updates on the company’s three-asset ADC portfolio targeting PTK7, MUC16 and SEZ6.
On this page, users can also locate Whitehawk’s annual reports on Form 10-K and quarterly reports on Form 10-Q, which typically contain more detailed discussions of the company’s oncology pipeline, risk factors, and financial condition. For investors interested in governance and compensation matters, proxy materials and related filings can provide additional context on board and executive oversight of the ADC development strategy.
Stock Titan enhances these documents with AI-powered summaries that highlight key points from lengthy filings, helping readers quickly understand major updates without having to parse every page. Real-time updates from the SEC’s EDGAR system ensure that new WHWK filings, including future 10-Ks, 10-Qs and 8-Ks, appear promptly. Users can also review insider transaction reports on Form 4, when available, to see reported trades by directors and officers.
Together, these resources give a structured view of how Whitehawk reports its financial performance, clinical progress and corporate decisions to regulators and the market.
Whitehawk Therapeutics reported first-quarter 2026 results with a net loss of $22.2 million, reflecting its transition to a pure clinical-stage antibody drug conjugate (ADC) company after selling its FYARRO business in 2025.
The company generated no revenue in the quarter versus $7.1 million a year earlier, when results included FYARRO sales and an $87.4 million gain on that divestiture. Operating expenses were $23.5 million, driven mainly by $17.2 million in research and development for its three ADC programs. Cash, cash equivalents and short-term investments totaled $123.0 million at March 31, 2026, and management believes existing resources can fund planned operations into 2028.
Whitehawk Therapeutics reported first quarter 2026 results, highlighting its transition to a pure R&D oncology company. Cash, cash equivalents and short-term investments were $123.0 million as of March 31, 2026, which the company anticipates will fund operations into 2028.
Whitehawk posted a net loss of $22.2 million for the quarter, compared with net income of $73.0 million a year earlier, when results included an $87.4 million gain on the sale of Aadi Subsidiary and $7.1 million of product sales. Research and development expenses rose to $17.2 million, driven in part by $5.3 million of development milestones under a WuXi Biologics license agreement.
Operationally, the company is enrolling Phase 1 trials for HWK‑007 and HWK‑016, plans to submit an IND for HWK‑206 in mid‑2026 with Phase 1 recruitment targeted for Q3 2026, and expects initial Phase 1 data for HWK‑007 and HWK‑016 in the first half of 2027.
Whitehawk Therapeutics, Inc. is holding its 2026 annual stockholder meeting virtually on June 11, 2026 at 1:00 p.m. Eastern Time. Holders of 49,428,177 common shares as of April 17, 2026 can vote online, by phone, by mail, or during the webcast.
Stockholders will elect three Class III directors to terms ending in 2029, cast an advisory vote on 2025 executive compensation, and vote on ratifying BDO USA, P.C. as independent auditor for 2026. The proxy also outlines board structure, committee memberships, director pay, and employment and severance terms for senior executives, including salary, bonus targets and equity incentives.
Whitehawk Therapeutics, Inc. Chief Financial Officer Scott M. Giacobello reported broker-assisted dispositions of common stock primarily to cover tax obligations from vesting equity awards. On April 15 and 16, he sold 77,000 shares at $3.86 and 141,600 shares at $4.13 per share, respectively. A footnote explains these represent sales to satisfy tax withholding obligations tied to restricted stock unit vesting, rather than discretionary open-market selling. After these transactions, he continues to hold 295,224 shares of common stock directly.
Whitehawk Therapeutics (WHWK) reported a Form 144 notice listing proposed sales of Common Stock and Restricted Stock Units. The filing shows a securities-to-be-sold entry dated 04/01/2026 with a line item of 473,902. It also records a sale by Scott M. Giacobello of 2,594 shares on 03/02/2026 with an associated figure of $8,585.10.
Whitehawk Therapeutics officer Bryan Ball reported broker-assisted sales of company common stock to cover taxes on vested restricted stock units. On April 13, he sold 26,389 shares at $3.46 per share, and on April 14 he sold 92,460 shares at $3.64 per share. A footnote clarifies these transactions were solely to satisfy tax withholding obligations related to RSU vesting, making them compensation-driven rather than discretionary portfolio sales. After these transactions, Ball directly held 397,106 shares of Whitehawk Therapeutics common stock.
Whitehawk Therapeutics insider Bryan Ball reported dispositions of company common stock that were executed solely to cover taxes on equity compensation. On April 9 and 10, he completed broker-assisted sales totaling 56,596 shares at prices between $3.43 and $3.57 per share.
The footnote explains these trades were conducted to satisfy tax withholding obligations arising from the vesting of restricted stock units, rather than discretionary open-market sales. After these transactions, Ball still directly holds 515,955 shares of Whitehawk Therapeutics common stock.
Whitehawk Therapeutics, Inc. director and chief executive officer David James Lennon reported selling 14,500 shares of common stock on April 9, 2026 at $3.38 per share. According to the filing, this broker-assisted sale was made solely to satisfy tax withholding obligations tied to vesting restricted stock units. After the transaction, he directly holds 518,622 shares of Whitehawk common stock.
Whitehawk Therapeutics (WHWK) filed a Form 144 reporting an intended sale of 366,532 Restricted Stock Units with an applicable date of 04/01/2026. The filing shows 1,834 shares of Common Stock were sold on 03/02/2026 for $6,069.80.